Affiliation:
1. Molecular Virology Department, Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Nicosia 2371, Cyprus
Abstract
Orally administered compounds represent the great majority of all pharmaceutical compounds produced for human use and are the most popular among patients since they are practical and easy to self-administer. Following ingestion, orally administered drugs begin a “perilous” journey down the gastrointestinal tract and their bioavailability is modulated by numerous factors. The gastrointestinal (GI) tract anatomy can modulate drug bioavailability and accounts for interpatient drug response heterogeneity. Furthermore, host genetics is a contributor to drug bioavailability modulation. Importantly, a component of the GI tract that has been gaining notoriety with regard to drug treatment interactions is the gut microbiota, which shares a two-way interaction with pharmaceutical compounds in that they can be influenced by and are able to influence administered drugs. Overall, orally administered drugs are a patient-friendly treatment option. However, during their journey down the GI tract, there are numerous host factors that can modulate drug bioavailability in a patient-specific manner.
Funder
The Cyprus Institute of Neurology and Genetics internal funding budget
Reference127 articles.
1. Homayun, B., Lin, X., and Choi, H.J. (2019). Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics, 11.
2. Drawing up and administering intramuscular injections: A review of the literature;Rodger;J. Adv. Nurs.,2000
3. Advances in Oral Drug Delivery;Alqahtani;Front. Pharmacol.,2021
4. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review;Vinarov;Eur. J. Pharm. Sci.,2021
5. An integrated catalog of reference genes in the human gut microbiome;Li;Nat. Biotechnol.,2014